Almara uses advanced AI and clinical bioinformatics to automate and accelerate the matching of patients to relevant clinical trials. The platform integrates large language models to accurately interpret complex medical queries against trial eligibility criteria in real-time. This technology provides healthcare professionals and patients with precise trial recommendations, improving access to oncology research opportunities.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients, particularly those in underprivileged communities, face significant barriers to accessing clinical trials due to lack of awareness, complex enrollment processes, and logistical challenges. This disparity limits access to potentially life-saving therapies and hinders the development of treatments that are representative of diverse populations.
Solution
Almara is an AI-driven platform designed to connect patients with clinical trials that are personalized to their individual medical profiles and preferences. The platform uses an advanced algorithm to analyze patient data, including medical history and genetics, to identify optimal trial matches. By streamlining the trial process and reducing administrative burdens for both patients and organizers, Almara aims to enhance access to clinical trials, especially for underserved communities. Almara also initiates educational programs, outreach, and partnerships to break down barriers and foster understanding of clinical trials.
Target Audience
The primary target audience includes patients seeking access to clinical trials, particularly those in underprivileged communities, as well as clinical trial organizers looking to streamline their processes and improve patient enrollment.
Features
- AI-driven algorithm for personalized clinical trial matching based on patient profiles, medical history, genetics, and preferences.
- Streamlined trial process to reduce administrative burdens for patients and organizers.
- Educational programs and outreach initiatives to improve awareness and access to clinical trials for underprivileged communities.
- Focus on diversity and patient-centricity to ensure trials represent the broader population.